Current location:Home > Metabolic Pipeline > Chemical Drugs

Chemical Drugs

Oral small-molecule therapies for comprehensive cardiometabolic disease management.
  • APPROVED IN CHINA
    Sitagliptin Phosphate Tablets
    Oral dipeptidyl peptidase-4 (DPP-4) inhibitor indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.

     

    MoA DPP-4i
    Indication Type 2 Diabetes
    Dosage Form Tablet (100mg)

     

  • APPROVED IN CHINA
    Linagliptin Tablets
    Oral DPP-4 inhibitor for improving glycemic control in adults with type 2 diabetes mellitus.
    MoA DPP-4i
    Indication Type 2 Diabetes
    Dosage Form Tablet (5mg)

     

  • APPROVED IN CHINA
    Sitagliptin Phosphate/Metformin Hydrochloride Tablets (II)
    Oral fixed-dose combination of sitagliptin phosphate and metformin hydrochloride tablet for improving glycemic control in adults with type 2 diabetes mellitus.
    MoA DPP-4i/Biguanides
    Indication Type 2 Diabetes
    Dosage Form Tablet (50 mg/850 mg, sitagliptin/metformin)

     

  • APPROVED IN CHINA
    Empagliflozin Tablets
    Oral SGLT2 inhibitor for improving glycemic control in patients with type 2 diabetes mellitus.
    MoA SGLT-2i
    Indication Type 2 Diabetes, Heart Failure
    Dosage Form Tablet (10mg)

     

  • PHASE 3 IN CHINA
    Bempedoic Acid Tablets
    Oral ACL inhibitor for reducing LDL-C in adults with hypercholesterolemia, including heterozygous familial hypercholesterolemia.
    MoA ACLi
    Indication Hyperlipidemia
    Dosage Form Tablet (180mg)

     

  • SUBMITTED IN CHINA
    Mesalamine Extended-Release Capsules
    Extended-release mesalamine capsules for the maintenance of remission of ulcerative colitis in adults.
    MoA PP2Ai
    Indication Ulcerative colitis
    Dosage Form Capsule (0.375g)